Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + vinorelbine as first-line treatment for driver-negative advanced elderly NSCLC
ChiCTR2100049487Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Beijing Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumabvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100049487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049487.